Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Results of AEGIS-I trial of CSL-112

Nov. 30, 2016

Ustekinumab treatment shows promise in giant cell arteritis

Nov. 30, 2016

AstraZeneca patents FLAP and leukotriene synthesis inhibitors

Nov. 25, 2016

Pfizer patents myeloperoxidase irreversible inhibitors

Nov. 24, 2016

Nippon Boehringer Ingelheim and Astellas launch Micatrio combination tablets in Japan

Nov. 21, 2016

Chinese scientists present FXR agonists

Nov. 17, 2016

Full results of EUCLID trial of ticagrelor in peripheral artery disease trial divulged

Nov. 16, 2016

RXFP1 agonist ML-290 as a potential treatment for acute myocardial infarction

Nov. 16, 2016

BGI-Shenzhen develops of calcium channel blockers

Nov. 11, 2016

TGFB1 may be behind coronary artery disease with glatiramer acetate treatment

Nov. 8, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...